{"schema_version":"secwatch.filing_event.v1","accession":"0000014272-23-000179","form_type":"8-K","ticker":"BMY","cik":"0000014272","company_name":"BRISTOL MYERS SQUIBB CO","filed_at":"2023-10-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.037816+00:00","generated_at":"2026-06-09T08:22:22.588871+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Bristol-Myers Q3 rev $10.97B; GAAP EPS $0.93, non-GAAP $2.00; Mirati acquisition","bullets":["Q3 revenues $10,966M, down 2% YoY (3% ex-FX); GAAP EPS $0.93 (+24%), non-GAAP EPS $2.00 (+1%).","In-line and new product portfolio revenue grew 8% YoY (7% ex-FX).","Acquired IPRD and licensing charges reduced GAAP and non-GAAP EPS by $0.03 per share.","Planned acquisition of Mirati Therapeutics to strengthen oncology pipeline; terms not disclosed.","Adjusted 2023 GAAP EPS guidance downward; raised midpoint of non-GAAP EPS guidance range."],"urls":{"canonical":"https://secwatch.observer/filing/0000014272-23-000179","json":"https://secwatch.observer/filing/0000014272-23-000179.json","markdown":"https://secwatch.observer/filing/0000014272-23-000179.md","text":"https://secwatch.observer/filing/0000014272-23-000179.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/0000014272-23-000179-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/bmy-20231026.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T08:22:22.588871+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ccfd04d5108947237a0a684e5719c4ac828df689","claim":"BRISTOL MYERS SQUIBB CO reported the third quarter of 2023 results: revenue $10,966, EPS 0.93.","evidence_excerpt":"business development opportunities that benefit patients.\" 1 Third Quarter $ amounts in millions, except per share amounts 2023 2022 Change Change Excl. F/X** Total Revenues $10,966 $11,218 (2) % (3) % Earnings per share - GAAP* 0.93 0.75 24 % N/A Earnings per share - Non-GAAP* 2.00 1.99 1 % N/A * GAAP and Non-GAAP earnings per share include the net impact of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/14272/000001427223000179/0000014272-23-000179-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$10,966"},{"label":"EPS","value":"0.93"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}